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c on c i s e c ommun i c a t i o n
Effective Antibiotic Conservation by
Emergency Antimicrobial Stewardship
During a Drug Shortage
Kevin Hsueh, MD;1 Maria Reyes, MD;1
Tamara Krekel, PharmD;2 Ed Casabar, PharmD;2
David J. Ritchie, PharmD;2,3 S. Reza Jafarzadeh, PhD;1
Amanda J. Hays, PharmD;4 Michael A. Lane, MD;1,4
Michael J. Durkin, MD1,5
We present the ﬁrst description of an antimicrobial stewardship
program (ASP) used to successfully manage a multi-antimicrobial
drug shortage. Without resorting to formulary restriction, mer-
openem utilization decreased by 69% and piperacillin-tazobactam by
73%. During the shortage period, hospital mortality decreased
(P= .03), while hospital length of stay remained unchanged.
Infect Control Hosp Epidemiol 2017;38:356–359
Despite being a common occurrence, very little has been
published on how healthcare institutions can address anti-
microbial shortages.1–4 Antimicrobial stewardship programs
(ASPs) have been proposed as ideally suited to deal with anti-
microbial shortages.5 To our knowledge, no publications have
quantiﬁed ways in which an ASP can impact drug utilization
during a shortage of antibiotics. We describe here the response of
an ASP to a critical multidrug antimicrobial shortage at a large
tertiary-care academic hospital as well as the subsequent effects
on antimicrobial use and hospital-level outcomes.
methods
Hospital Description and Baseline Antimicrobial
Stewardship Activities
Barnes-Jewish Hospital (BJH) is a 1,252-bed tertiary care
academic medical center located in St. Louis, Missouri. The ASP
at BJH was started in 1984, and at the time the shortage began in
2015, the ASP was composed of 2 infectious diseases (ID) trained
pharmacists who provided practice guidelines and guidance to
other pharmacy staff. Clinical pharmacists tasked with reviewing
antimicrobial use as part of their standard duties were embedded
with most services, though they did not track their interventions.
No pre-existing interventions or use restrictions were in place
for most antimicrobials, including the drugs in short supply.
Previous shortages had been addressed throughmessaging alone.
Shortage Timeline and Interventions
Meropenem and imipenem. On October 5, 2015,
procurement failure and low stock of meropenem (MEM)
led to a drug shortage alert from the pharmacy leadership.
Attempts to purchase imipenem-cilastatin (IPM), an
alternative carbapenem, were unsuccessful. Pharmacy and
medical leadership formed a task force comprised of 2 ID
physicians, 2 ID-trained clinical pharmacists, an ID pharmacy
resident, and an ID fellow. Interventions were executed in a
staggered fashion (Supplementary Figure 1), starting with an
informational campaign composed of a hospital-wide e-mail
announcement, messages to clinical pharmacy, and guidance
on alternatives to MEM. Subsequently, active drug-stock
tracking was implemented for all anti-pseudomonal
antibiotics. Finally, physician-directed prospective auditing of
MEM and IPM use was implemented. During the shortage,
the pharmacy acquired as much additional drug stock as was
made available from suppliers. Shortage conditions ended on
January 1, 2016, after a regular supply was re-established.
Piperacillin-tazobactam. On October 20, 2015, lack of
purchasable supplies led to an additional shortage declaration
for piperacillin-tazobactam (TZP). The shortage task force
expanded its scope to include TZP utilizing an enhanced
approach. In addition to aggressive messaging to the clinical
pharmacy, specialties with high TZP usage, including general
surgery and emergency medicine, were identiﬁed. Treatment
protocols utilizing TZP were identiﬁed andmodiﬁed to replace
TZP with alternative agents, accompanied by corresponding
changes to electronic order sets. Prospective auditing of TZP
use was also performed through December 28, 2015.
Physician-directed prospective auditing of antimicrobial
use. The electronic medical record was queried to identify
all patients actively prescribed the drugs affected by the
shortage. Each chart was then reviewed by a task force member
to identify the indications, microbiologic sensitivities, and
severity of illness. In cases in which a substitution was
considered safe and reasonable, the primary team was called
and a change was recommended. The ﬁnal decision regarding
whether to accept or reject this recommendation remained
with the primary team. The frequency of review ranged from 1
to 3 times per week and was adjusted by task force leadership
based on shortage severity.
Study Design
Data on antibiotic utilization were retrospectively obtained
for all patients hospitalized at BJH between May 1 and
December 31, 2015. Antibiotic data were analyzed individually
as well as categorized into broad-spectrum gram-negative
antibiotics or anti-methicillin-resistant Staphylococcus aureus
(MRSA) antibiotics. Broad-spectrum antibiotics included
cefepime (FEP), IPM, MEM, TZP, and ertapenem. A
nti-MRSA antibiotics included daptomycin, ceftaroline, line-
zolid, and vancomycin. Antibiotic use was captured in days of
therapy (DOT), mirroring the deﬁnitions used in the CDC
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National Healthcare Safety Network (NHSN) Antimicrobial
Use surveillance module.6 Antimicrobial use was calculated
and plotted in DOT per 1,000 patient days (PD).7 The number
of audits was tracked by date and plotted against antibiotic
utilization ﬁgures.
Daily antibiotic use for each antibiotic and antibiotic group
were plotted, and pre- and post-intervention use were
compared. To assess overall impact on antibiotic use, linear
regression models with autoregressive integrated moving
average (ARIMA) errors were ﬁt to the natural logarithm of
daily rates, accounting for the correlation of errors over time.
Covariates included calendar day and indicator variables for
intervention status for each day. Intervention dates for MEM
and TZP were deﬁned as the dates when shortages were ﬁrst
announced to medical staff (ie, the ﬁrst intervention). Percent
changes in rates were then estimated from the ﬁtted models
where the coefﬁcients were assessed to be statistically
signiﬁcantly different from null (ie, zero).
To assess the impact of interventions on remaining supply,
we calculated the days of use remaining (DUR), deﬁned as the
cumulative amount of stocked drug (in grams) divided by the
standard daily pseudomonal dose, ie, the quantity of drug used
in 24 hours to treat a pseudomonal infection in an adult with
normal renal function. For MEM, this dosage was 3 g
(1 g administered every 8 hours); for IPM the dosage was 2 g
(0.5 g every 6 hours); for FEP, the dosage was 6 g (2 g every
8 hours); and for TZP, the dosage was 18 gm (4.5 g every
6 hours).
Change in antibiotic expenditure during the shortage was
calculated by comparing antibiotic use during the shortage
with use over the prior 5 months. The estimated expenditure
per 1,000 PD for those periods was calculated by multiplying
DOT per 1,000 PD with the standard daily pseudomonal dose
and the publicly reported average wholesale price (AWP) per
gram of drug.8
All-cause mortality for the drug-shortage period (October–
December 2015) was compared to the mortality rates for
October–December for the preceding 3 years. Clostridium
difﬁcile infection (CDI) rates were obtained as NHSN lab-ID
reported cases per 1,000 PD. Statistical signiﬁcance was asses-
sed using the Student t test.
Regression models with ARIMA errors adjustment was
performed using R version 3.2.4 (R Foundation for Statistical
Computing, Vienna, Austria). All other analyses were per-
formed using SAS version 9.4 (SAS Institute, Cary, NC), and
graphs were produced using SPSS Statistics version 20 (IBM,
Armonk, NY). P values < .05 were considered statistically
signiﬁcant. This study was approved by the Washington
University Institutional Review Board.
results
Substantial declines in antimicrobial use were observed for all
the drugs affected by the shortage during the study period.
Decreases in antimicrobial use corresponded with episodes of
physician-directed audit and feedback, which totaled 273
audits (172 for MEM, 25 for IPM, 76 for TZP) (Figure 1).
Audits were successful in triggering antimicrobial use changes
23% of the time for MEM, 26% of the time for IPM, and 40%
of the time for TZP. Shortage intervention periods were
associated with statistically signiﬁcant decreases in antibiotic
utilization for MEM, IPM, and TZP, with a compensatory
increase in FEP (Table 1). Despite signiﬁcant changes in MEM,
TZP, and FEP use, overall, broad-spectrum, anti-MRSA, and
ﬂuoroquinolone agent use did not change over the course of
the interventions.
ﬁgure 1. Antimicrobial use during a drug shortage: impact of number of daily drug use audits performed. Legend: ○, meropenem
(MEM); ◊, piperacillin-tazobactam (TZP). *Bars= no. drug-use audits performed that day.
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Stockpiles of MEM and IPM increased rapidly after shortage
interventions began (Supplementary Figure 2). MEM stores
increased from a low of 100 DUR to >3,000 DUR. FEP stock
remained stable throughout the shortage, with approximately
1,000 DUR available on average. TZP supplies averaged 200
DUR throughout the shortage.
Antibiotic expenditure declined by $3,223 per 1,000 PD
(Table 2). MEM use declined from a pre-shortage average of
65.3 to 20 DOT per 1,000 PD, while TZP use decreased from
38.8 to 16.5 DOT per 1,000 PD. FEP use increased from 107.3
to 150.9 DOT per 1,000 PD during the shortage, and smaller
increases were observed for IPM (1.7 to 2.7 DOT per 1,000
PD) and ertapenem (15 to 19 DOT per 1,000 PD).
The unadjusted hospital mortality rate for the October–
December period decreased to 4.09 deaths per 1,000 PD
for the shortage year 2015, compared with 4.67, 4.78, and
4.60 for the same months in previous years (P= .03). Length of
stay did not signiﬁcantly change for the October–December
period in the shortage year compared with the same periods
in the 3 previous years. Clostridium difﬁcile infection (CDI) rates
did not differ signiﬁcantly between the shortage period com-
pared with the same months in 2015 (data not shown; P= .86).
discussion
Antimicrobial stewardship programs have many well-
established beneﬁts. Our study is the ﬁrst to characterize
another useful function: effective conservation of antibiotics
during drug shortages. Messaging and changes in guidelines
and decision support were a very effective method at ﬁrst for
reducing antibiotic use. However, prospective intervention
was required to sustain reduced antibiotic utilization rates. In
this study, systematic changes, such as the guideline and
decision support changes used to intervene on TZP utilization,
appear to have had a more sustainable effect than messaging
alone (as was done for MEM).
Prospective auditing clearly reduced antimicrobial use, if
transiently, which potentially provided the edge needed to
prevent stock depletion. However, auditing was labor inten-
sive. A team of 6 clinicians was required to audit the shortage
drugs, likely due to the large patient volume at BJH. The
system used was also the most rapidly deployable option rather
than the most efﬁcient.
Unsurprisingly, our study demonstrates that when speciﬁc
drugs are targeted for conservation, there is a corresponding
increase in the use of alternative drugs. This response, collo-
quially referred to as “squeezing the balloon,” is common and
expected during both drug shortages and routine
antimicrobial stewardship efforts.
Gross hospital outcomes and CDI rates showed no dis-
cernible immediate deleterious effect of the shortage and
conservation efforts during the study period; however, long-
term effects of our emergency stewardship efforts remain to be
determined. This is a well-known limitation to antimicrobial
table 1. Antimicrobial Use During a Drug Shortage: Impact on Antimicrobial Use by Drug-Targeted Intervention Period
Percent Change in Utilization (95% CI)a
Antibiotic Type MEM/IPM Intervention Period TZP Intervention Period Study Period Excluding Intervention Periods
Cefepime 29.4 (16.1 to 44.3) 6.8 (−3.9 to 18.6) 0.0 (−0.1 to 0.0)
Meropenem −69.3 (−78.0 to −57.2) NA 0.0 (−0.2 to 0.1)
Piperacillin-tazobactam NA −72.8 (−76.1 to 69.1) 0.0 (0.0 to 0.1)
Broad-spectrum β-lactam agentsb −2.0 (−8.3 to 4.6) −4.6 (−9.7 to 0.8) 0.0 (0.0 to 0.1)
Anti-MRSA agentsc 3.6 (−3.6 to 11.3) −2.2 (−8.6 to 4.6) 0.0 (0.0 to 0.1)
Fluoroquinolone agents 15.9 (−1.2 to 35.9) −4.6 (−17.5 to 10.4) 0.0 (-0.1 to 0.1)
NOTE. CI, conﬁdence interval; MEM, meropenem; IPM, imipenem; TZP, piperacillin-tazobactam; NA, not available; MRSA, methicillin-
resistant Staphylococcus aureus.
aIntervals that exclude 0 are statistically signiﬁcant.
bBroad-spectrum β-lactams: cefepime (FEP), IPM, MEM, TZP, and ertapenem.
cAnti–methicillin-resistant Staphylococcus aureus agents: daptomycin, ceftaroline, linezolid, and vancomycin.
table 2. The Impact of an Antimicrobial Shortage and Subsequent Conservation Efforts on Estimated Hospital Antimicrobial Expenditure
Drug
Estimated Average AWP
Cost Per DOT
Pre-Shortage Utilization
(DOT/1,000 PD)
Shortage Utilization
(DOT/1,000 PD)
Change in Estimated
Expenditure Per 1,000 PD
Cefepime $91.49 107.3 150.9 $3,989
Meropenem $126.21 65.3 20 − $5,717
Imipenem-cilastatin $88.16 1.7 2.7 $88
Piperacillin-tazobactam $91.50 38.8 16.5 − $2,041
Ertapenem $114.63 15 19 $458
Estimated total change in expenditure per 1000 PD − $3,223
NOTE. AWP, average wholesale price; DOT, days of therapy; PD, patient days.
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stewardship monitoring: the effects of microbial susceptibility
patterns may be subtle, occurring months afterward.9,10
Persistent stewardship programs are also needed so that
ongoing monitoring can detect delayed effects and allow for
corrective responses.
Our study has several limitations. The brief shortage dura-
tion limits our ability to make a more detailed assessment of
rare outcomes such as antimicrobial-resistant infections or
infection-related mortality. Additionally, our interventions
were bundled, making it challenging to determine the effects of
individual elements. However, initial communications to
medical providers were highly effective in reducing antibiotic
use. Appropriateness of use was not monitored during this
study. Under shortage conditions, the imperative was deemed
to be conserving antibiotics in short supply for cases in which
alternatives would be ineffective. Recommendations were
often made to take patients off otherwise appropriate anti-
biotics in favor of effective non-shortage drugs. Lastly, our
estimated drug costs were based on average wholesale price,
rather than actual expenditure, and we did not consider anti-
biotic stockpiling, drug price changes related to the shortage,
or emergency purchases of alternative antibiotics. For exam-
ple, emergency supplies of ceftazidime, ceftazidime-avibactam,
and ceftolozane-tazobactam were purchased, but a negligible
amount of these agents was utilized.
In conclusion, antimicrobial stewardship is a successful
method of conserving antibiotics during a drug shortage. Our
efforts dramatically reduced selected antibiotic utilization,
increased reserve stock of critically short antibiotics, saved phar-
macy costs, and did not negatively impact overall patient length of
stay or mortality. Hospitals facing critical drug shortages should
consider utilizing antimicrobial stewardship teams to conserve
medications while maintaining a high standard of patient care.
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